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Letter to the Editor 
Re: High nevus counts confer a favorable prognosis in melanoma patients by S Ribero and 
co-workers, published in the International Journal of Cancer, 2015 (Online 21 March 2015). 
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The study by S Ribero and co-workers is welcome because only few studies have examined 
the outcome of cutaneous melanoma patients according to host characteristics associated 
with greater risk to be diagnosed with this cancer 
1
. Number and size of nevi is the strongest 
risk factor for melanoma occurrence, and despite a lack of evidence, it is generally assumed 
that higher risk of melanoma occurrence would also mean a higher risk of melanoma death. 
Because of this assumption, subjects with high nevus count are recommended to have 
regular skin examinations so that detection of melanoma at an early stage may prevent the 
occurrence of late stage, potentially lethal melanoma. However, contrary to assumptions, 
the study of Ribero et al rather suggests that a high nevus count could be associated with a 
lower risk to die from melanoma, and this lower risk was in a multivariate analysis 
independent of age, sex, anatomic location, tumour phenotype and sentinel lymph node 
status. Ribero et al concluded that in patients with an excessive number of nevi, melanoma 
would have a less aggressive biological behaviour.  
 
This study raises several concerns. Multivariate models done by Ribero et al included 
Breslow thickness as a continuous variable. Use of a continuous variable assumes a linear 
relationship between increasing thickness and melanoma specific mortality. However, this 
relationship rather follows an inverse exponential curve, with steep rise in mortality from 0.1 
to 2 mm thickness, and a progressively less steep rise until 4 mm. After 4 mm, the 
relationship slowly stabilizes 
2
. In this regard, adjustment done with a continuous variable 
will fail to completely remove the greater melanoma survival of the high nevus group 
associated with a greater proportion of thin melanoma in this group. Multivariate models 
including thickness categories as defined by the American Joint Committee on Cancer 
3
 
would be more adequate.   
 
Should a correct multivariate model confirm results obtained by Ribero et al, we believe that 
overdiagnosis of melanoma in subjects with high number of nevi could represent an 
alternative explanation to their results. Subjects with numerous nevi are recommended to 
have regular skin examinations. Unfortunately skin screening leads to more frequent 
removal of thin, non-metastasising indolent tumours that would never be life threatening 
during subject’s lifetime (i.e., length time melanoma)
4
. Screen-detected indolent melanoma 
represents overdiagnosis that contributes to raising the incidence of melanoma in many 
light-skinned populations 
5
. Overdiagnosis is also fuelled by the “diagnosis drift” whereby 
benign pigmented lesions are increasingly classified as stage 1 melanoma 
6
. The 
consequence of more skin screening in subjects exhibiting large numbers of nevi is a higher 
rate of early stage melanoma, many of which are indolent. In Ribero et al study, melanomas 
in patients with high nevus count are significantly thinner, non-ulcerative, and of low mitotic 
index, all histological features that indicate the greater prevalence of indolent melanoma in 
this group of subjects.  
 
It is well known that patients with screen-detected cancer have a survival advantage over 
patients with clinical cancer that is not explained by the clinical or histological characteristics 
of tumours or by patient’s risk factors. The milder biological aggressiveness of screen-
detected cancers is well documented for breast and for prostate cancers 
7-9
. The survival 
advantage conferred by mild biological aggressiveness is substantial, in the order of 40 to 
90% greater survival for cancer-specific and all-cause survival in the case of mammography-
detected breast cancer, and probably even more for PSA-detected prostate cancer. We are 
not aware of a study that has estimated the survival advantage of screen-detected 
melanoma. But population level statistics show that the survival of melanoma patients 
increases with the incidence of melanoma, and not with decreases in melanoma mortality 
10
. 
The dependence of survival on melanoma incidence rather than on melanoma mortality 
represents indirect evidence that the sluggish clinical behaviour of many screen-detected 
melanomas would be similar to that of many screen-detected breast and prostate cancers.  
 
Hence, irrespective of risk factors known to be associated with the clinical course of 
melanoma, a greater proportion of screen-detected melanomas in the group of subjects 
with excessive nevus count could be partly responsible for the higher melanoma-specific 
survival.  
 
In conclusion, the possibility of an association between a high nevus count and a more 
favourable melanoma-specific survival should be viewed with caution.    
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